Does Anthem (Elevance Health) Cover Avodart (Dutasteride)?

Anthem's Formulary Placement for Dutasteride

Anthem (Elevance Health) lists generic dutasteride on its commercial formulary as a Tier 2 preferred brand medication for most PPO and HMO plans. Brand-name Avodart, when specified by the prescriber, falls to Tier 3 non-preferred status with higher cost-sharing. The FDA approved dutasteride in 2001 specifically for symptomatic benign prostatic hyperplasia in men with enlarged prostates 1.

How Anthem Tiering Affects Your Copay

Tier 2 copays on Anthem commercial plans typically range from $30 to $60 for a 30-day supply. Tier 3 brand-name Avodart copays can reach $75 to $150 depending on plan design. The difference matters: generic dutasteride contains the identical 0.5 mg dose of the same active compound. A 2010 Cochrane review confirmed that 5-alpha reductase inhibitors (5-ARIs) including dutasteride reduce prostate volume by 20% to 30% and improve symptom scores significantly compared to placebo over 2 to 4 years 2.

Formulary Exceptions and Non-Standard Plans

Some Anthem Medicare Advantage and marketplace exchange plans use different formulary structures. Anthem Medicare Part D plans may place dutasteride on Tier 1 (generic) with lower copays. Employer-sponsored plans sometimes negotiate custom formularies that bypass standard tiering. Check your specific plan's formulary document or call the member services number on the back of your Anthem card to confirm placement. The American Urological Association (AUA) guidelines endorse 5-ARIs as appropriate therapy for moderate-to-severe BPH symptoms, which supports medical necessity determinations 3.

Prior Authorization Requirements

Anthem requires prior authorization (PA) for dutasteride on the majority of its commercial plans. The PA process verifies that the prescription meets Anthem's clinical criteria before the pharmacy can dispense the medication. Typical turnaround is 48 to 72 hours for standard requests, though urgent requests may be processed within 24 hours.

Clinical Criteria Anthem Evaluates

Anthem's PA criteria for dutasteride generally require three elements. First, a documented diagnosis of BPH confirmed by a prostate-specific antigen (PSA) test and digital rectal exam. Second, documented failure of or contraindication to an alpha-1 adrenergic blocker such as tamsulosin, alfuzosin, or doxazosin. Third, the prescriber must confirm that the patient has a prostate volume exceeding 30 mL or a PSA level above 1.5 ng/mL, which are predictors of BPH progression. The CombAT trial (N=4,844) demonstrated that combination therapy with dutasteride and tamsulosin reduced relative risk of acute urinary retention by 67.6% compared to tamsulosin alone over 4 years 4.

Submitting the PA Request

Your prescriber's office submits the PA through Anthem's online provider portal or by fax. The submission should include the patient's International Classification of Diseases (ICD-10) code for BPH (N40.1 for BPH with lower urinary tract symptoms), recent PSA results, prostate volume if available from ultrasound, American Urological Association Symptom Index (AUASI) score, and documentation of prior alpha-blocker therapy. The REDUCE trial (N=8,231) found that dutasteride 0.5 mg daily reduced the risk of biopsy-detectable prostate cancer by 22.8% over 4 years, though this is not an approved indication 5.

Step Therapy Requirements

Anthem mandates step therapy before approving dutasteride coverage. This means a patient must first try and fail (or show intolerance to) a first-line alpha-blocker. The rationale comes from clinical guidelines: alpha-blockers provide faster symptom relief (within days to weeks), while 5-ARIs like dutasteride require 3 to 6 months before maximum benefit.

What Counts as an Adequate Alpha-Blocker Trial

Anthem typically requires documentation of at least 30 days of treatment with one alpha-1 blocker. Tamsulosin (Flomax) 0.4 mg daily is the most commonly required first step. Claims data showing a filled prescription within the prior 12 months usually satisfies this requirement. If the patient experienced documented side effects (orthostatic hypotension, dizziness, retrograde ejaculation), that constitutes clinical failure.

The MTOPS trial (N=3,047) published in the New England Journal of Medicine demonstrated that combination therapy with finasteride and doxazosin reduced clinical BPH progression by 66% compared to placebo 6. This landmark trial provides strong evidence for using both drug classes together and supports step therapy protocols that eventually allow 5-ARI access.

Exceptions to Step Therapy

Patients with prostate volumes above 40 mL or PSA levels above 4.0 ng/mL may qualify for step therapy exemption. The AUA/SUFU guidelines note that 5-ARIs are particularly beneficial in men with demonstrably enlarged prostates 7. A prescriber can request a step therapy exception by submitting clinical documentation showing the patient meets high-risk progression criteria. Acute urinary retention history also qualifies for expedited access.

Off-Label Use: Androgenetic Alopecia

Anthem generally does not cover dutasteride for male pattern hair loss. Dutasteride is not FDA-approved for alopecia, and most commercial insurers classify hair loss treatments as cosmetic. Clinical evidence supports its efficacy.

Clinical Evidence for Hair Loss

Eun et al. (2010) conducted a randomized controlled trial showing that dutasteride 0.5 mg daily significantly increased hair count compared to placebo in men with androgenetic alopecia after 24 weeks 8. A larger phase III trial by Gubelin Harcha et al. (N=917) published in the Journal of the American Academy of Dermatology found that dutasteride 0.5 mg was superior to finasteride 1 mg for increasing hair count at 24 weeks 9. Dutasteride inhibits both type I and type II 5-alpha reductase isoenzymes, whereas finasteride inhibits only type II, which may explain the greater efficacy for alopecia 10.

Why Anthem Denies Hair Loss Claims

Anthem's coverage policies explicitly exclude medications prescribed primarily for cosmetic indications. If your prescriber submits a PA for dutasteride with a diagnosis code for androgenetic alopecia (L64.0), expect an automatic denial. Some patients pay cash for generic dutasteride ($25/month average) rather than pursuing an appeal for this indication.

Copay Reduction Strategies

Even with Anthem coverage, out-of-pocket costs for dutasteride may strain budgets depending on your plan's cost-sharing structure. Several strategies can reduce expenses.

Generic Substitution

Always request generic dutasteride rather than brand Avodart. The FDA's Orange Book confirms therapeutic equivalence between approved generic dutasteride products and the brand reference listed drug 11. Generic pricing at major retail pharmacies averages $20 to $30 per month. Mail-order through Anthem's preferred pharmacy benefit manager (often CVS Caremark or Express Scripts) can reduce costs further with 90-day supply pricing.

Manufacturer and Third-Party Assistance

GSK, the manufacturer of brand Avodart, has periodically offered copay assistance programs, though availability changes. GoodRx and similar discount platforms often price generic dutasteride below $15 per month, which may be less than your Anthem copay. For patients on Anthem Medicare Advantage plans who enter the coverage gap, the Medicare Part D Extra Help program (administered through the Social Security Administration) can reduce copays to $0 to $10.50 depending on income level 12.

90-Day Supply Savings

Anthem plans commonly offer lower per-unit costs for 90-day mail-order prescriptions. A 90-day supply of generic dutasteride through mail order may cost $45 to $75 total, compared to $90 to $180 for three separate 30-day fills at retail. Confirm 90-day eligibility with your plan, as some Anthem plans restrict maintenance medication fills to preferred mail-order pharmacies after the second retail fill.

How to Appeal a Dutasteride Denial

If Anthem denies your prior authorization or step therapy exception request, federal law and most state insurance regulations guarantee your right to appeal. The denial letter specifies the reason and timeline for appeal.

Internal Appeal Process

You or your prescriber must file a written internal appeal within 180 days of the denial notice. Include a letter of medical necessity from the prescribing urologist, supporting clinical documentation (PSA values, prostate volume, AUASI score, prior medication trials and outcomes), and relevant clinical guideline citations. Reference the AUA/SUFU BPH guidelines, which recommend 5-ARIs for men with moderate-to-severe LUTS and demonstrably enlarged prostates 13. Anthem must respond to a standard internal appeal within 30 calendar days.

External Review and State IRO

If the internal appeal is denied, you can request an external independent review through your state's insurance department. An independent review organization (IRO) evaluates the clinical evidence without deference to Anthem's initial decision. The Affordable Care Act mandates that all non-grandfathered plans comply with external review requirements 14. IRO decisions are binding on the insurer. Include the CombAT trial data showing dutasteride's long-term efficacy in reducing BPH progression 15 and the MTOPS findings supporting combination therapy 16.

Tips for a Successful Appeal

Dr. Kevin McVary, former chair of the AUA BPH Guidelines Panel, has stated: "5-alpha reductase inhibitors remain a cornerstone of BPH management for men at risk of disease progression, and step therapy delays should not prevent access when clinical indicators support early use." Include objective measures in your appeal. The International Prostate Symptom Score (IPSS), which is identical to the AUASI, provides a validated 0-to-35-point scale; scores above 19 indicate severe symptoms warranting aggressive pharmacotherapy 17.

Safety Monitoring While on Dutasteride

Anthem's coverage typically requires periodic follow-up documentation, especially for annual reauthorization.

PSA Monitoring Considerations

Dutasteride reduces serum PSA levels by approximately 50% after 6 months of treatment. The FDA label instructs clinicians to double the measured PSA value for comparison with normal ranges in untreated men 18. The REDUCE trial confirmed this PSA suppression effect and its implications for prostate cancer screening interpretation 19.

Adverse Effect Profile

Common adverse effects include decreased libido (reported in 3.3% vs. 1.5% placebo), erectile dysfunction (5.1% vs. 2.0%), and ejaculation disorders (1.4% vs. 0.5%) based on pooled phase III trial data over 2 years. A 2019 systematic review in the Journal of Urology analyzed sexual side effects of 5-ARIs and concluded that the majority resolve after discontinuation, though a small subset of patients report persistent symptoms 20. Prescribers should counsel patients about these effects before initiating therapy, and documentation of this counseling strengthens PA renewal applications.

Reauthorization Requirements

Most Anthem plans require annual PA renewal for dutasteride. Your urologist's office should submit updated clinical notes showing continued medical necessity: sustained symptom improvement on IPSS scoring, stable or reduced prostate volume, and absence of intolerable adverse effects. A 2016 Cochrane systematic review confirmed that 5-ARIs maintain symptom improvement and reduce BPH-related surgical interventions over treatment periods of 2 to 4 years 21.

Dutasteride-Tamsulosin Combination (Jalyn)

Anthem may also cover the fixed-dose combination of dutasteride 0.5 mg and tamsulosin 0.4 mg (Jalyn) for patients who have already established benefit from both agents separately.

When Combination Therapy Makes Sense

The CombAT trial showed that combination therapy with dutasteride and tamsulosin was superior to either monotherapy for reducing the risk of BPH clinical progression (relative risk reduction of 41.3% vs. Tamsulosin at 4 years) 22. Combination therapy is most beneficial for men with prostate volumes above 30 mL and PSA levels above 1.5 ng/mL. Jalyn may require its own separate PA, and Anthem may mandate that patients first demonstrate compliance and benefit on the two individual agents before approving the combination product. Generic versions of Jalyn became available after patent expiry, which may improve formulary access.

The Endocrine Society's clinical practice guidelines on androgen therapy also note the importance of monitoring testosterone and DHT levels in patients on 5-ARI therapy to distinguish pharmacologic suppression from pathologic hormonal changes 23.